SIRT6 and breast cancer: It has been reported that SIRT6 confers paclitaxel and epirubicin resistance in MCF-7 cells, which has suggested that SIRT6 is a potential marker and therapeutic target for paclitaxel- and epirubicin-resistant breast cancer [103].